|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1996-11-04 |
Treatment patterns and clinical outcomes of Recombinant Follicle Stimulating Hormone in South Korean patients who received Controlled Ovarian Hyper-stimulation: Results from a retrospective observational chart review study
An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
100 项与 Ferring Pharmaceuticals Korea Co., Ltd. 相关的临床结果
0 项与 Ferring Pharmaceuticals Korea Co., Ltd. 相关的专利(医药)
100 项与 Ferring Pharmaceuticals Korea Co., Ltd. 相关的药物交易
100 项与 Ferring Pharmaceuticals Korea Co., Ltd. 相关的转化医学